Low potential of circulating interleukin 1 receptor antagonist as a prediction marker for squamous cell carcinoma of the head and neckShow others and affiliations
2021 (English)In: Journal of Oral Pathology & Medicine, ISSN 0904-2512, E-ISSN 1600-0714, Vol. 50, no 8, p. 785-794Article in journal (Refereed) Published
Abstract [en]
Background: Circulating markers are attractive molecules for prognosis and management of cancer that allow sequential monitoring of patients during and after treatment. Based on previous protein profiling data, circulating interleukin 1 receptor antagonist (IL-1Ra) was evaluated as a potential diagnostic and prognostic marker for squamous cell carcinomas of the head and neck (SCCHN). In this study, we aimed at confirming the clinical relevance of plasma IL-1Ra in SCCHN and exploring its potential as a prediction marker for SCCHN.
Methods: Plasma from 87 patients with SCCHN, control plasma from 28 healthy individuals and pre-diagnostic plasma from 44 patients with squamous cell carcinoma of the oral tongue (SCCOT) and 88 matched controls were analysed with IL-1Ra electrochemiluminescence immunoassays from mesoscale diagnostics.
Results: Plasma IL-1Ra was found to be up-regulated in patients with oral tongue, gingiva and base of tongue tumours compared to healthy individuals (p < 0.01). IL-1Ra levels positively correlated with tumour size (p < 0.01) and body mass index (p = 0.013). Comparing pre-diagnostic plasma to the matched controls, similar IL1-Ra levels were seen (p = 0.05).
Conclusion: The anti-inflammatory cytokine IL-1Ra could be a diagnostic marker for SCCHN, whereas its potential as a cancer prediction marker was not supported by our data.
Place, publisher, year, edition, pages
John Wiley & Sons, 2021. Vol. 50, no 8, p. 785-794
Keywords [en]
IL-1Ra, plasma, squamous cell carcinoma
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-183579DOI: 10.1111/jop.13187ISI: 000648481300001PubMedID: 33880804Scopus ID: 2-s2.0-85105414094OAI: oai:DiVA.org:umu-183579DiVA, id: diva2:1559111
Funder
Cancerforskningsfonden i NorrlandSwedish Cancer Society, 20 0754 PjF 01HRegion VästerbottenSwedish Research Council, VR 2017-006502021-06-012021-06-012021-12-30Bibliographically approved